Moderated By Eyal Rivlin Lev Hakongressim, Weizmann Science Park, Ness Ziona May 2008.

Slides:



Advertisements
Similar presentations
Microbiological Validation
Advertisements

The New GMP Annex 11 and Chapter 4 Deadline for coming into operation: 30 June 2011.
Sterile Product Manufacturing
BS EN ISO Cleanrooms & associated controlled environments- Part 3: Metrology and test methods DIS.
Why does PAT need Rapid Microbiology Methods? S.Lonardi, P.J.Newby, D.Ribeiro, B.Johnson PAT Subcommittee meeting October 23, 2002.
1 ASQ Keynote February 13, 2006 A Look Back at 2006 The year of the hurricane Organizational Change National and District Changes in programs Adverse Drug.
WHO - PSM Air Handling Systems Heating Ventilation and Air Conditioning (HVAC) – Part 1 Pharmaceutical Quality, Good manufacturing Practice & Bioequivalence.
1 Utility Systems Process Systems – ‘Direct Impact Systems’ Contact the Product Contact Materials that will Ultimately Become Part of the Product Could.
Sterile Drug Process Inspections
Facility Design and CGMP Considerations for Cell Therapy Products
Aseptic Processing Mrs Robyn Isaacson
Media Fill Protocol Luisa Stoppa
SAE AS9100 Quality Systems - Aerospace Model for Quality Assurance
Basic Principles of GMP
Sterilized, Validated, Documented and Pyrogen Tested Wipers
DISCOVER DEVELOP MANUFACTURE CMO’s Challenges and Strategies in Aseptic Manufacturing Jixing Wang, Ph.D. GMP Summit 2014 September 25-26, 2014 Valencia.
MCC PRESENTATION - GMP MANUFACTURING ENVIRONMENTS
QC/QA Mary Malarkey Director, Division of Case Management Office of Compliance and Biologics Quality Center for Biologics Evaluation and Research March.
HYGIENE CONTROL IN THE BREWING INDUSTRY
Rob Packard, President Slide 1 of 30 Bioburden Failure Analysis An E. coli strain being plated for identification.
World Health Organization
World Health Organization
Preventing Contamination: Aseptic Processing Risk Factors Richard L. Friedman, M.S. FDA/CDER 10/22/02 OPS Advisory Committee/ Aseptic Processing.
Radiopharmaceutical Production
World Health Organization
Process Simulation Media Fills
Basic Principles of GMP
Module 13Slide 1 of 48 WHO - EDM Part Three Basic Principles of GMP Sterile Production.
Changes without Prior Approval Breakout Session Summary Rick Smith Aventis Pasteur, Inc.
Module 1, Part 3: Process validation Slide 1 of 22 © WHO – EDM – 12/2001 Validation Part 3: Process validation Supplementary Training Modules on Good Manufacturing.
Services and Supplies to Meet USP Requirements Patricia C. Kienle, RPh, MPA, FASHP Director, Accreditation and Medication Safety Cardinal Health Pharmacy.
© Pharmaceutical Consultancy Services, All rights reserved. ENVIRONMENTAL MONITORING (VIABLES) Jaap Koster 1.
Part I: Introduction and overview
Compounding Issues in Neuromodulation December 9, 2012 North American Neuromodulation Society 16 th Annual Scientific Meeting Wynn Hotel, Las Vegas Nevada.
© Institute for International Research, Inc All rights reserved. Module 3: Aseptic Processing.
Horizontal Laminar Air Flow Vertical Laminar Air Flow.
© Pharmaceutical Consultancy Services, All rights reserved. MEDIA FILLS Jaap Koster.
Organization and Implementation of a National Regulatory Program for the Control of Radiation Sources Inspection Part II.
© Pharmaceutical Consultancy Services, All rights reserved. MEDIA FILLS Jaap Koster.
Important informations
... Clear and simple Parenteral Overviews Parenteral Manufacturing Overview Company Confidential Copyright © 2000 Eli Lilly and Company Agenda Parenteral.
© Institute for International Research, Inc All rights reserved. Module 6: Manufacturing Throughput.
2 IMPACT - THE FIRE PERMIT = Hot Work Permit 3 Welcome ! This course is linked to the use of IMPACT, so it is assumed that: You know how to use IMPACT.
Expectations for Facilities & cGMPs Biological Response Modifiers Advisory Committee Meeting October 9, 2003 Nicholas Obiri, Ph.D. CBER.
Smallpox Vaccine Administration  Learning Objectives Demonstrate appropriate vaccine administration techniques Demonstrate appropriate vaccine administration.
HIPAA Security John Parmigiani Director HIPAA Compliance Services CTG HealthCare Solutions, Inc.
FDA Preliminary Concept Paper Sterile Drug Products Produced by Aseptic Processing This presentation summarizes the content of PDA’s official position,
Pharmaceutical Quality Control & current Good Manufacturing Practice PHT 436 Lecture 4.
| Onderstepoort Biological Products © |22nd February 2013Page 58 √ OBP √ 2008.
Environmental Control and Developing a Science-based Monitoring Program Richard L. Friedman, M.S. FDA/CDER.
Wyeth-Ayerst Pharmaceuticals1 CLEANING VALIDATION Microbial Monitoring Anthony M. Cundell Ph. D. Associate Director, QA Microbiological Development & Statistics.
Sterile Products Lab PHT 434
USP <1116> and its impact on Microbiology
Pharmaceutical Quality Control & current Good Manufacturing Practice
EU GMP Annex 1 and ISO Prepared by Tim Sandle.
Author: Nurul Azyyati Sabri
MCC PRESENTATION - GMP MANUFACTURING ENVIRONMENTS
Quality Control and Assurance
FDA Guide To Aseptic Processing
Author: Nurul Azyyati Sabri
MHRA GMP Inspection Deficiency Data Trend 2016
Aseptic Technique Definitions.
Annex 1: Changes & Interpretations
Regulatory update Overview and Introduction Annex 1 Revision
Basic Principles of GMP
Treatment – Ultraviolet (UV)
Sterile Products Lab PHT 434
Aseptic Processing 2019: Trends and Challenges
Manufacture of Sterile Medicinal Products: Practical Examples
Manufacture of Sterile Medicinal Products: ‘Annex 1’ - DRAFT
Presentation transcript:

Moderated By Eyal Rivlin Lev Hakongressim, Weizmann Science Park, Ness Ziona May 2008

The new annex will be implemented by 1 st March 2009,Capping requirement March GMP Annex 1 has been revised and updated in four main areas: –Classification table for environmental cleanliness of clean rooms –Guidance on media simulations –Guidance on bioburden monitoring –Guidance on capping of liquid and freeze-dried vials Introduction

Editorial changes Laminar air flow becomes uni-directional air flow. Clean room becomes cleanroom. Capping of freeze dryed and liquid vials.

Classification table for environmental cleanliness of clean rooms – Annex 1(2003)

Classification table for environmental cleanliness of clean rooms The continued requirement for monitoring 5 micron particles generated the most comments. A Non EU agency (FDA) does not require this monitoring. An occasional indication of ≥5 micron particle counts may be false counts due to electronic noise, stray light, coincidence, etc. Why not remove it ? Lack of scientific rationale to remove this requirement. Published papers provide data to support continued requirement to monitor 5 micron particales.

monitoring ≥5 micron particles (advantages) Consecutive or regular low levels of ≥5 micron particles is an indicator of a possible contamination event and should be investigated. Such events may indicate early failure of the HVAC system, filling equipement or bad practice during routine operation or machine set-up. An important diagnostic tool for early detection of failure. Not monitoring ≥5 micron particles would indicate the company has a High risk appetite.

monitoring ≥5 micron particles - decision It was accepted that the previous limits were not statistically valid. The limits have been changed to 20 for grade A and 29 for grade B. Alert limits and out of trend limits may need to be revised when implementing cont. monitoring.

Classification table for environmental cleanliness of clean rooms- Revised Annex 1 (2008)

≥5 micron particles- summary operationalAt restoperationalAt restgrade 20 11A B

Guidance on media simulations The limits were brought to line with the FDA aseptic guidance. The updated limit appears to have been well accepted by inspectors and industry 2003: 2008: Investigation following revalidation InvestigationFilled units 1-Fewer than 5000 Units Units 21More than Units

Guidance on capping of freeze-dried and liquid vials 1. Partially stoppered vials should be maintained under grade A conditions at all times until the stopper is fully inserted. 2. The container closure system for aseptically filled vials is not fully integral until the aluminium cap has been crimped into place on the stoppered vial. Crimping of the cap should therefore be performed as soon as possibly after stopper insertion

Guidance on capping of freeze-dried and liquid vials 3.Vial capping can be undertaken as an aseptic process using sterilised caps or as a clean process outside the aseptic core. where this later approach is adopted, vials should be protected by grade A conditions up to the point of leaving the aseptic processing area, and thereafter stoppered vials should be protected with a Grade A air supply until the cap has been crimped.

Guidance on capping of freeze-dried and liquid vials 4.Vials with missing or displaced stoppers should be rejected prior to capping. Where human intervention is required at the capping station, appropriate technology should be used to prevent direct contact with the vials and to minimize microbial contamination. 5. Restricted access barriers and isolators may be beneficial (it is more than a recommendation) in assuring the required conditions and minimizing direct human intervention into the capping operation.

Bioburden prior to sterilization Clarification of requirements: The bioburden should be monitored before sterilization. There should be working limits on contamination immediately before sterilization, which are related to the efficiency of the method to be used. Bioburden assay should be performed on each batch for both aseptically filled product and terminally sterilized products.

Q&A ?

THE END !